None listed
Conditions
Interventions
Drug : 20mg of nafamostat mesilate (Futhan, SK Chemicals, Seoul, Korea) dissolved in 500ml of 5% dextrose solution was used in both group. Infusion began within an hour before ERCP and was continued f
Sponsors
Pusan National University Yangsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients with an intact papilla and known or suspected pancreatobiliary disease, who are candidates for therapeutic or diagnostic biliary ERCP at a single tertiary referral center (Pusan National University Yangsan Hospital), were scheduled to participate in the study.
Exclusion criteria
Exclusion criteria: Patients were excluded for any of the following reasons: age younger than 18 years, previous history of precut or biliary sphicterotomy, previous history of biliary or pancreatic stenting, repeated ERCP, clinical evidence of acute pancreatitis at the time of procedure, treatment with nafamostat mesilate or other protease inhibitors in the last 7 days, pregnancy and refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| post ERCP pancreatitis incidence, post ERCP pancreatitis severity, serum amylase/lipase level, abdominal pain | — |
Secondary
| Measure | Time frame |
|---|---|
| diagnostic procedures, therapeutic procedures, examination time, and number of injection or cannulation of the pancreatic duct, placement of prophylactic pancreatic stent | — |
Countries
Korea, Republic of
Contacts
Public ContactSU JIN KIM
Pusan National University Yangsan Hospital
Outcome results
None listed